Literature DB >> 26926628

In Vitro Analysis of the Interaction between Atovaquone and Proguanil against Liver Stage Malaria Parasites.

Lídia Barata1, Pascal Houzé2, Khadija Boutbibe2, Gigliola Zanghi3, Jean-François Franetich3, Dominique Mazier4, Jérôme Clain5.   

Abstract

The interaction between atovaquone and proguanil has never been studied against liver stage malaria, which is the main target of this drug combination when used for chemoprevention. Using human hepatocytes lacking cytochrome P450 activity, and thus avoiding proguanil metabolizing into potent cycloguanil, we show in vitro that the atovaquone-proguanil combination synergistically inhibits the growth of rodent Plasmodium yoelii parasites. These results provide a pharmacological basis for the high efficacy of atovaquone-proguanil used as malaria chemoprevention.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26926628      PMCID： PMC4914690          DOI： 10.1128/AAC.01685-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression.

Authors:  Hervé Le Nagard; Corine Vincent; France Mentré; Jacques Le Bras
Journal:  Comput Methods Programs Biomed       Date:  2010-09-09       Impact factor: 5.428

2.  Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity.

Authors:  Olivier Silvie; Eric Rubinstein; Jean-François Franetich; Michel Prenant; Elodie Belnoue; Laurent Rénia; Laurent Hannoun; Wijnand Eling; Shoshana Levy; Claude Boucheix; Dominique Mazier
Journal:  Nat Med       Date:  2002-12-16       Impact factor: 53.440

3.  Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.

Authors:  Gregory A Deye; R Scott Miller; Lori Miller; Carola J Salas; Donna Tosh; Louis Macareo; Bryan L Smith; Susan Fracisco; Emily G Clemens; Jittawadee Murphy; Jason C Sousa; J Stephen Dumler; Alan J Magill
Journal:  Clin Infect Dis       Date:  2011-11-03       Impact factor: 9.079

4.  Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro.

Authors:  C J Canfield; M Pudney; W E Gutteridge
Journal:  Exp Parasitol       Date:  1995-05       Impact factor: 2.011

5.  Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model.

Authors:  J D Berman; R Nielsen; J D Chulay; M Dowler; K C Kain; K E Kester; J Williams; A C Whelen; M J Shmuklarsky
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 Jul-Aug       Impact factor: 2.184

6.  In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes.

Authors:  A H Lu; Y Shu; S L Huang; W Wang; D S Ou-Yang; H H Zhou
Journal:  Acta Pharmacol Sin       Date:  2000-08       Impact factor: 6.150

7.  Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Authors:  B B Knowles; C C Howe; D P Aden
Journal:  Science       Date:  1980-07-25       Impact factor: 47.728

Review 8.  Cell lines: a tool for in vitro drug metabolism studies.

Authors:  M T Donato; A Lahoz; J V Castell; M J Gómez-Lechón
Journal:  Curr Drug Metab       Date:  2008-01       Impact factor: 3.731

9.  A mechanism for the synergistic antimalarial action of atovaquone and proguanil.

Authors:  I K Srivastava; A B Vaidya
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

10.  Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain.

Authors:  Samir Yalaoui; Sergine Zougbédé; Stéphanie Charrin; Olivier Silvie; Cécile Arduise; Khemais Farhati; Claude Boucheix; Dominique Mazier; Eric Rubinstein; Patrick Froissard
Journal:  PLoS Pathog       Date:  2008-02-29       Impact factor: 6.823
View more
  4 in total

1.  Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone.

Authors:  Tina S Skinner-Adams; John H Ryan; Katherine T Andrews; Gillian M Fisher; Andrew G Riches; Oliver E Hutt; Karen E Jarvis; Tony Wilson; Mark von Itzstein; Pradeep Chopra; Yevgeniya Antonova-Koch; Stephan Meister; Elizabeth A Winzeler; Mary Clarke; David A Fidock; Jeremy N Burrows
Journal:  Commun Biol       Date:  2019-05-03

2.  Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasites.

Authors:  Dorjbal Dorjsuren; Richard T Eastman; Anton Simeonov; David A Fidock; Kathryn J Wicht; Daniel Jansen; Daniel C Talley; Benjamin A Sigmon; Alexey V Zakharov; Norma Roncal; Andrew T Girvin; Yevgeniya Antonova-Koch; Paul M Will; Pranav Shah; Hongmao Sun; Carleen Klumpp-Thomas; Sachel Mok; Tomas Yeo; Stephan Meister; Juan Jose Marugan; Leila S Ross; Xin Xu; David J Maloney; Ajit Jadhav; Bryan T Mott; Richard J Sciotti; Elizabeth A Winzeler; Norman C Waters; Robert F Campbell; Wenwei Huang
Journal:  Sci Rep       Date:  2021-01-22       Impact factor: 4.379

3.  Pre-erythrocytic Activity of M5717 in Monotherapy and Combination in Preclinical Plasmodium Infection Models.

Authors:  Diana Fontinha; Francisca Arez; Isabella Ramella Gal; Gonçalo Nogueira; Diana Moita; Tobias Hyun Ho Baeurle; Catarina Brito; Thomas Spangenberg; Paula M Alves; Miguel Prudêncio
Journal:  ACS Infect Dis       Date:  2022-03-21       Impact factor: 5.084

4.  Peptides derived from Plasmodium falciparum leucine-rich repeat 1 bind to serine/threonine phosphatase type 1 and inhibit parasite growth in vitro.

Authors:  Christine Pierrot; Xiguang Zhang; Gigliola Zanghi; Aline Fréville; Angelita Rebollo; Jamal Khalife
Journal:  Drug Des Devel Ther       Date:  2018-01-09       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.